Research programme: PARP-inhibitors - 2X Oncology
Latest Information Update: 21 Feb 2017
At a glance
- Originator Unknown
- Developer 2X Oncology
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer